Is BofA Merrill Positive On Shares of Eidos Therapeutics (EIDX)?

July 16, 2018 - By Matthew Richard

Why Has BofA Merrill Given Eidos Therapeutics (EIDX) a $24.0 Price Target

In a note issued on 16 July, BofA Merrill analyst has today has initiated coverage for Eidos Therapeutics (EIDX) shares with a “Neutral” rating. The target price per share is set to $24.0.

The stock increased 5.78% or $1.2 during the last trading session, reaching $21.97. About 112,693 shares traded. Eidos Therapeutics, Inc. (EIDX) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin amyloidosis (ATTR). The company has market cap of $807.42 million. It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. It currently has negative earnings. The firm was incorporated in 2013 and is headquartered in San Francisco, California.

More notable recent Eidos Therapeutics, Inc. (NASDAQ:EIDX) news were published by: Bizjournals.com which released: “Kezar Life Sciences stock jumps 18% after IPO raises $75M” on June 21, 2018, also 247Wallst.com with their article: “Top Analyst Upgrades and Downgrades: American Tower, Darden Restaurants, FedEx, Hasbro, Parker-Hannifin, Wells …” published on July 16, 2018, Bizjournals.com published: “Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M” on June 28, 2018. More interesting news about Eidos Therapeutics, Inc. (NASDAQ:EIDX) were released by: Bizjournals.com and their article: “Eidos Therapeutics soars after IPO tops targets, raises $106M” published on June 20, 2018 as well as Schaeffersresearch.com‘s news article titled: “2 Biopharma Stocks Expected to Skyrocket” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.